[go: up one dir, main page]

WO2018160021A1 - Composition contenant un extrait d'oxya chinensis sinuosa ou un composé isolé de celui-ci en tant que principe actif, pour la prévention, le soulagement ou le traitement des rides cutanées - Google Patents

Composition contenant un extrait d'oxya chinensis sinuosa ou un composé isolé de celui-ci en tant que principe actif, pour la prévention, le soulagement ou le traitement des rides cutanées Download PDF

Info

Publication number
WO2018160021A1
WO2018160021A1 PCT/KR2018/002501 KR2018002501W WO2018160021A1 WO 2018160021 A1 WO2018160021 A1 WO 2018160021A1 KR 2018002501 W KR2018002501 W KR 2018002501W WO 2018160021 A1 WO2018160021 A1 WO 2018160021A1
Authority
WO
WIPO (PCT)
Prior art keywords
formula
compound
extract
acceptable salt
skin wrinkles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2018/002501
Other languages
English (en)
Korean (ko)
Inventor
채성욱
임아랑
나민균
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Korea Institute of Oriental Medicine KIOM
Industry and Academy Cooperation In Chungnam National University
Original Assignee
Korea Institute of Oriental Medicine KIOM
Industry and Academy Cooperation In Chungnam National University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Korea Institute of Oriental Medicine KIOM, Industry and Academy Cooperation In Chungnam National University filed Critical Korea Institute of Oriental Medicine KIOM
Publication of WO2018160021A1 publication Critical patent/WO2018160021A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/63—Arthropods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
    • A61K8/987—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of species other than mammals or birds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/20—Natural extracts
    • A23V2250/204—Animal extracts

Definitions

  • the present invention is rice locust chinensis sinuosa ) relates to a composition for preventing, improving or treating skin wrinkles containing an extract or a compound separated therefrom as an active ingredient.
  • the skin protects the organs of the body from stimulation of the external environment and plays an important role in maintaining homeostasis such as temperature control.
  • the skin is aging due to various internal and external factors, and is classified into endogenous aging due to genetic causes and exogenous aging due to environmental causes.
  • photoaging means aging by ultraviolet (UV).
  • UV ultraviolet
  • ozone layer destruction due to environmental pollution has increased the amount of ultraviolet rays, and thus research on photoaging has been focused.
  • cosmetic features such as roughness, loss of elasticity, wrinkles and irregular pigmentation are observed.
  • the main research field of photo-aging is about the change of skin wrinkles.
  • MMPs collagen degrading enzymes
  • rice locusts are 30 ⁇ 38cm in length, yellowish green in color, but yellowish brown in head and chest. Compound eyes are oval, glossy greyish brown. There are three narrow grooves on the pronotum and brown vertical lines on both sides. The wings are yellowish brown and longer than the tip of the belly but do not fly very much. Inhabits grasses near rice fields or farmland. Occurs once a year, wintering in the ground. The pellets are wrapped in a gelatinous membrane. The mature nymph has a fourth scab, and its length is about 30mm. The number of pesticides used as a major pest of rice has decreased, but gradually increased. It occurred on the Yellow Sea in 1930 and bought eggs from the government. It is distributed in Korea, Japan, and China.
  • Korean Patent No. 1648612 discloses a method for producing a diet food composition comprising a rice locust component
  • Korean Patent Publication No. 2010-0002661 discloses a functional complex including hyaluronic acid and a method for preparing the same, There is no disclosure related to the prevention, improvement or treatment of skin wrinkles containing the rice locust extract of the invention or a compound isolated therefrom as an active ingredient.
  • the present invention has been made in accordance with the above requirements, and the present invention provides a compound of formula 1 or an acceptable salt thereof; A compound of formula 2 or an acceptable salt thereof; A compound of formula 3 or an acceptable salt thereof; Or byeomettugi (Oxya comprising at least one compound selected from compounds of formula 1-3 chinensis sinuosa ) relates to a composition for preventing, improving or treating skin wrinkles containing the extract as an active ingredient, wherein the compounds of the formulas 1 to 3 and rice locust extracts have no cytotoxicity and have increased expression of MMP-1 by UV irradiation.
  • the present invention has been completed by confirming that it significantly reduces.
  • the present invention is a compound of Formula 1 or an acceptable salt thereof; A compound of formula 2 or an acceptable salt thereof; A compound of formula 3 or an acceptable salt thereof; Or byeomettugi (Oxya comprising at least one compound selected from compounds of formula 1-3 chinensis sinuosa ) provides a health functional food composition for the prevention or improvement of skin wrinkles containing the extract as an active ingredient.
  • the present invention provides a compound of formula 1 or an acceptable salt thereof; A compound of formula 2 or an acceptable salt thereof; A compound of formula 3 or an acceptable salt thereof; Or byeomettugi (Oxya comprising at least one compound selected from compounds of formula 1-3 chinensis sinuosa ) provides a pharmaceutical composition for preventing or treating skin wrinkles containing the extract as an active ingredient.
  • the present invention provides a compound of Formula 1 or an acceptable salt thereof; A compound of formula 2 or an acceptable salt thereof; A compound of formula 3 or an acceptable salt thereof; Or as the active ingredient for the prevention, improvement or treatment composition for the skin wrinkles containing byeomettugi (Oxya chinensis sinuosa) extract comprising one or more compounds selected from compounds of formula 1-3 as an active ingredient it has no cytotoxicity Since the effect of inhibiting the expression of MMP-1 is remarkable, it can be usefully used for health functional food or medicine for preventing, improving or treating skin wrinkles.
  • byeomettugi Oxya chinensis sinuosa
  • Figure 2 is a result of confirming the cell survival rate (%) after treating the compound derived from the rice locust extract of the present invention (Compound A (Formula 1), Compound B (Formula 2) and Compound C (Formula 3)) by concentration.
  • Figure 3 is the result of confirming the expression change of MMP-1 after treating the rice locust extract of the present invention by concentration.
  • A is the result of H & E staining
  • B is the result of Masson's trichome staining.
  • the present invention is a compound of Formula 1 or an acceptable salt thereof; A compound of Formula 2 or an acceptable salt thereof; A compound of formula 3 or an acceptable salt thereof; Or rice grasshopper containing one or more compounds selected from compounds of the formula 1 to 3 ( Oxya chinensis sinuosa ) relates to a health functional food composition for preventing or improving skin wrinkles containing the extract as an active ingredient.
  • the compounds of Formulas 1 to 3 are preferably extracted from rice locust, but are not limited thereto, and may be extracted or synthesized from other natural products.
  • the rice locust extract may be prepared by a method comprising the following steps, but is not limited thereto:
  • the extraction solvent in the step (1) is preferably selected from water, lower alcohols of C 1 ⁇ C 4 or mixtures thereof, more preferably ethanol, even more preferably 70% (v / v) ethanol It is not limited to this.
  • the extraction method may use all conventional methods known in the art, such as filtration, hot water extraction, immersion extraction, reflux cooling extraction and ultrasonic extraction.
  • the extraction solvent is preferably extracted by adding 1 to 20 times the weight of the dried rice locust, more preferably 5 to 15 times.
  • Extraction temperature is preferably 4 to 50 °C but is not limited thereto.
  • the extraction time is preferably 0.5 to 10 hours, more preferably 0.5 to 5 hours, most preferably 1 hour, but is not limited thereto.
  • the vacuum concentration in step (3) is preferably used as a vacuum vacuum concentrator or a vacuum rotary evaporator, but not always limited thereto.
  • the drying is preferably reduced pressure drying, vacuum drying, boiling drying, spray drying or freeze drying, but is not limited thereto.
  • the dietary supplement composition is characterized by inhibiting the expression of MMP-1 or MMP-9.
  • the health functional food composition may be prepared in any one formulation selected from powder, granules, pills, tablets, capsules, candy, syrups and beverages, but is not limited thereto.
  • the health functional food composition of the present invention may be prepared by adding one or more selected from the compounds of the formula (1-3) derived from rice locust extract or rice locust extract as it is or mixing with other food or food ingredients, and according to a conventional method as appropriate Can be prepared.
  • foods to which one or more selected from the compounds of Formulas 1 to 3 derived from the rice locust extract may be added include caramel, meat, sausage, bread, chocolate, candy, snacks, confectionary, pizza, ramen, other noodles, gum, ice cream Dairy products, including various kinds of soups, beverages, tea, drinks, alcoholic beverages and vitamin complexes can be any one of the forms selected, including all the health functional foods in the ordinary sense. That is, the kind of food is not particularly limited.
  • the dietary supplement composition includes various nutrients, vitamins, minerals (electrolytes), synthetic and natural flavors, colorants and enhancers (cheese, chocolate, etc.), pectic acid and salts thereof, alkonic acid and salts thereof, organic acids, protective colloids. Thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated drinks and the like. It may also contain pulp for the production of natural fruit juices and vegetable drinks. The above components can be used independently or in combination.
  • the health functional food composition of the present invention may contain various flavors or natural carbohydrates, etc.
  • the natural carbohydrate is glucose, monosaccharides such as fructose, disaccharides such as maltose, sucrose, and dextrin, Polysaccharides such as cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol.
  • the ratio of the said natural carbohydrate is not important, it is preferable that it is 0.01-0.04g with respect to 100g of the composition of this invention, More preferably, it contains 0.02-0.03g, but it is not limited to this.
  • the sweetening agent natural sweetening agents such as tautin and stevia extract, synthetic sweetening agents such as saccharin and aspartame, and the like can be used.
  • the present invention provides a compound of Formula 1 or an acceptable salt thereof; A compound of formula 2 or an acceptable salt thereof; A compound of formula 3 or an acceptable salt thereof; Or byeomettugi (Oxya comprising at least one compound selected from compounds of formula 1-3 chinensis sinuosa ) relates to a pharmaceutical composition for preventing or treating skin wrinkles containing the extract as an active ingredient.
  • the pharmaceutical composition of the present invention may further comprise a pharmaceutically acceptable carrier, excipient or diluent.
  • Pharmaceutically acceptable carriers included in the pharmaceutical composition of the present invention are conventionally used in the preparation, saline solution, sterile water, Ringer's solution, buffered saline solution, dextrose solution, maltodextrin solution, glycerol, ethanol, lactose, dex Straw, sucrose, sorbitol, mannitol, starch, acacia rubber, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, syrups, methyl cellulose, methylhydroxybenzoate, propyl Hydroxybenzoate, talc, magnesium stearate and mineral oil, and the like.
  • composition of the present invention may be administered orally or parenterally, and the parenteral administration may be administered by injection or application to the skin.
  • suitable dosages of the pharmaceutical compositions of the present invention may be prescribed in various ways depending on factors such as the formulation method, mode of administration, age, weight, sex, morbidity, condition of food, time of administration, route of administration, rate of excretion and response to response of the patient. Can be.
  • Rice locust (4.87 kg) was extracted with ethanol containing 1% (v / v) acetic acid, and then distilled under reduced pressure to obtain 421.8 g of brown locust ethanol extract.
  • Ethanol extract (421.8 g) was extracted using hexane / ethyl acetate 100: 0 (6 L), 80:20 (6 L), 60:40 (6 L), 40:60 (6 L) and 20: using VLC (vacuum liquid chromatography). 80 (6 L) (v: v); Chloroform / methanol 100: 0 (6 L), 80:20 (6 L), 60:40 (6 L), 40:60 (6 L) and 20:80 (6 L) (v: v) gradient gradient elution conditions and methanol washing Six small fractions were obtained through the conditions (A to F).
  • the D fraction (35.7 g) was purified by hexane / ethyl acetate 100: 0 (6 L), 85:15 (6 L), 75:25 (6 L) and 50:50 (6 L) using VLC (vacuum liquid chromatography). v); 7 small fractions with chloroform / methanol concentration gradient elution conditions of 85:15 (6 L), 80:20 (6 L), 67:33 (6 L) and 50:50 (6 L) (v: v) was obtained (D-1 to D-7).
  • the D-5 fraction (18.3 g) was subjected to concentration gradient elution conditions of acetonitrile / water (10: 90-60: 40, 8160 mL) using MPLC (medium pressure liquid chromatography), and acetonitrile washing conditions. Small fractions were obtained (D-5-1 to D-5-6).
  • MMP-1 Cell viability and expression level of MMP-1 were analyzed using HaCaT cells. It was incubated in a medium containing mycin (penicillin-streptomycin; PS, Gibco) at 37 °C, 5% CO 2 conditions.
  • mycin penicillin-streptomycin; PS, Gibco
  • the hairless mice were used after 6 weeks old male hairless mice (male HR-1, hairless mice, Japan SLC, Inc.) were purchased from a central laboratory animal and adapted for 1 week. Healthy animals were used for testing by observing general conditions during the adaptation period.
  • the breeding environment was maintained at a temperature of 23 ⁇ 3 °C, a humidity of 50 ⁇ 5% and a contrast cycle of 12 hours (07: 00-19: 00 / lighting time).
  • 6 animals per group were kept in polycarbonate cages (200 ⁇ 320 ⁇ 145 mm, Three-shine Co., Daejeon, Korea), and the feed was free of 5L79 (Charles river, USA).
  • Sample administration was conducted in three groups: control group, UV-treated group (UV-vehicle), rice locust extract (BMG) administration group. Sample administration was performed by oral administration using a mouse zone. The administration period was a total of 12 weeks for 5 days a week.
  • UV irradiation was carried out three times a week for 12 weeks in the experimental group, except for the control group, the UVB lamp (Mineralight UV Display lamp, UVP, USA) was used. UV irradiation dose is 60 mJ / cm 2 for 1-4 weeks, 90 mJ / cm 2 for 5-8 weeks 9-12 weeks were examined at 120 mJ / cm 2 for 12 weeks. The amount of ultraviolet radiation was controlled by the irradiation time after measuring the amount of light using a photometer (Delta OHM, Italy).
  • the cultured HaCaT cells were treated by diluting each sample by concentration for 24 hours, and treated with MTS assay (CellTiter Aqueous One Solution Cell proliferation assay kit, 3- (4,5-dimethylthiazol-2-yl) -5- ( Microcarboxy reader at 490 nm with 3-carboxymethoxyphenyl) -2- (4-sulfophynyl) -2H-tetrazolium, inner salt; MTS, Promega Co. Madison, WI, USA) technique (Molecular Devices, Sunnyvale, CA, USA) Was measured.
  • MTS assay CellTiter Aqueous One Solution Cell proliferation assay kit, 3- (4,5-dimethylthiazol-2-yl) -5- ( Microcarboxy reader at 490 nm with 3-carboxymethoxyphenyl) -2- (4-sulfophynyl) -2H-tetrazolium, inner salt; MTS, Promega Co. Madison, WI, USA) technique (Molecular Device
  • the cell survival rate in the UVB irradiation group was lower than in the control group without any treatment, and after the UVB irradiation, the relative cell survival rate when the sample of the present invention (rice locust extract and the compound of Formulas 1 to 3) was treated.
  • the relative cell survival rate when the sample of the present invention (rice locust extract and the compound of Formulas 1 to 3) was treated.
  • the rice locust extract of the present invention and the compound of Formulas 1 to 3 were found to have little cytotoxicity.
  • the rice locust extract of the present invention and the compounds of Formulas 1 to 3 were each treated by concentration. Thereafter, ultraviolet (UV) irradiation, the culture supernatant was collected and centrifuged for 5 minutes at 13,000 rpm. Then, the supernatant was taken and subjected to fluorescence assay using an ELISA kit to quantitatively analyze the expression level of MMP-1.
  • UV ultraviolet
  • the epidermal thickness was measured by using a microscope equipped with a thickness from the keratin layer of the tissue subjected to H & E staining to the epidermal cell basement membrane.
  • the UV irradiation group had a stratum corneum as compared with the control group, and the epidermal thickness was also increased.
  • the rice locust extract (BMG) administration group had a stratum corneum as compared to the UV irradiation group. It was alleviated and the epidermal thickness was also decreased.
  • MMPs Collagen degrading enzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Birds (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Insects & Arthropods (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

La présente invention concerne une composition pour la prévention, le soulagement ou le traitement des rides cutanées, la composition contenant, en tant que principe actif, un extrait d'Oxya chinensis sinuosa comprenant un composé de formule chimique 1 ou son sel acceptable, un composé de formule chimique 2 ou son sel acceptable, un composé de formule chimique 3 ou son sel acceptable, ou au moins un composé choisi parmi les composés de formules chimiques 1 à 3. La composition supprime une lésion cellulaire provoquée par une exposition aux ultraviolets et inhibe remarquablement l'expression de MMP-1, et peut donc être utilisée en tant qu'alicament bon pour la santé ou un produit médicinal pour la prévention, le soulagement ou le traitement des rides cutanées.
PCT/KR2018/002501 2017-02-28 2018-02-28 Composition contenant un extrait d'oxya chinensis sinuosa ou un composé isolé de celui-ci en tant que principe actif, pour la prévention, le soulagement ou le traitement des rides cutanées Ceased WO2018160021A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020170026548 2017-02-28
KR10-2017-0026548 2017-02-28

Publications (1)

Publication Number Publication Date
WO2018160021A1 true WO2018160021A1 (fr) 2018-09-07

Family

ID=63370140

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2018/002501 Ceased WO2018160021A1 (fr) 2017-02-28 2018-02-28 Composition contenant un extrait d'oxya chinensis sinuosa ou un composé isolé de celui-ci en tant que principe actif, pour la prévention, le soulagement ou le traitement des rides cutanées

Country Status (2)

Country Link
KR (1) KR101995220B1 (fr)
WO (1) WO2018160021A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102561683B1 (ko) * 2021-01-29 2023-08-01 한국원자력연구원 벼메뚜기 추출물을 포함하는 경구 투여용 조성물

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003252739A (ja) * 2002-02-26 2003-09-10 Mikimoto Pharmaceut Co Ltd 美白剤および美白用皮膚外用剤
CN102285958A (zh) * 2011-04-21 2011-12-21 李国玉 一组多巴胺多聚体和其衍生物及其制备方法和医药用途
KR20160147293A (ko) * 2015-06-15 2016-12-23 이정복 항노화, 항산화, 또는 항염 효능을 갖는 누에고치 유래의 펩타이드 또는 펩타이드 유도체를 함유하는 피부외용제 및 화장료 조성물

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003252739A (ja) * 2002-02-26 2003-09-10 Mikimoto Pharmaceut Co Ltd 美白剤および美白用皮膚外用剤
CN102285958A (zh) * 2011-04-21 2011-12-21 李国玉 一组多巴胺多聚体和其衍生物及其制备方法和医药用途
KR20160147293A (ko) * 2015-06-15 2016-12-23 이정복 항노화, 항산화, 또는 항염 효능을 갖는 누에고치 유래의 펩타이드 또는 펩타이드 유도체를 함유하는 피부외용제 및 화장료 조성물

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
TADA, T.: "Potential cosme tyrosinase inhibitory activity Cicada", CRYPTOTYMPANA TUSTULAT JOURNAL OF OLEO SCIENCE, 2002 *
XU, M.-Z ., ANTIOXIDANT AND ANTI-INF N-ACETYLDOPAMINE DIMERS FROM PERIOSTRACUI BIOORGANIC & MEDICINAL CHEMISTRY, 2006 *

Also Published As

Publication number Publication date
KR101995220B1 (ko) 2019-07-02
KR20180099569A (ko) 2018-09-05

Similar Documents

Publication Publication Date Title
WO2020060060A1 (fr) Composition cosmétique comprenant un extrait de racine adventive de centella asiatica en tant que principe actif pour le blanchiment de la peau et la réduction des rides
WO2011007943A1 (fr) Procédé de production de nouveaux extraits de gynostemma pentaphyllum présentant des quantités accrues de damuline a et de damuline b, et composition pharmaceutique utilisant ces extraits pour traiter des maladies métaboliques
CN104114176A (zh) 美拉德反应抑制剂
KR20180037163A (ko) 당 비함유 파인애플 추출물과 그 제조 방법 및 그 용도
WO2023113111A1 (fr) Composition de blanchiment de la peau pour soulager le mélasme, les taches de vieillesse, etc. à l'aide d'une gomme mastic soluble dans l'eau
WO2018004252A1 (fr) Composition pour activer la croissance des poils ou inhiber la chute des poils utilisant un extrait de feuille de rosmarinus officinalis (romarin)
WO2020052571A1 (fr) Utilisation d'extrait de combretum micranthum dans des produits cosmétiques
WO2021033994A1 (fr) Composition comprenant un extrait de salvia miltiorrhiza ou de paeonia lactiflora utilisé comme principe actif pour la prévention ou le traitement d'un trouble du métabolisme des lipides
KR101385191B1 (ko) 치커리 추출물의 근육 손상 예방, 치료 또는 개선을 위한 용도
WO2018160021A1 (fr) Composition contenant un extrait d'oxya chinensis sinuosa ou un composé isolé de celui-ci en tant que principe actif, pour la prévention, le soulagement ou le traitement des rides cutanées
WO2016200002A1 (fr) Composition pour le traitement du cancer de la peau ou la suppression des métastases
WO2025009748A1 (fr) Composition antioxydante et anti-inflammatoire comprenant un extrait de feuille de carotte à l'eau de mer volcanique en tant que principe actif
WO2019172626A1 (fr) Composition pour l'hydratation de la peau et la réduction de rides, contenant un extrait de mélange d'herbes médicinales comme principe actif
WO2019022478A2 (fr) Composition contenant un extrait de gryllus bimaculatus en tant que principe actif pour améliorer les rides ou pour hydrater la peau
WO2023249155A1 (fr) Composition anti-glycation comprenant du décursinol en tant que principe actif
WO2022050819A1 (fr) Composition anti-inflammatoire pour réduire les rides cutanées et hydrater et activer la régénération de la peau, contenant, en tant que principe actif, un extrait d'huile de krill traitée par une enzyme
WO2023167367A1 (fr) Composition d'éclaircissement de la peau et de réduction des rides cutanées à l'aide de curcumine soluble dans l'eau et d'un extrait de son de blé
KR102202729B1 (ko) 안토시아닌-폴리사카라이드 복합체를 유효성분으로 포함하는, 노화 또는 노화 관련 질환 예방 또는 치료용 약학적 조성물
KR102843794B1 (ko) 유색미 추출물을 유효성분으로 포함하는 피부 주름의 예방, 개선 또는 치료용 조성물
KR101526435B1 (ko) 머루근 추출물을 포함하는 미백용 조성물
WO2019022476A2 (fr) Composition contenant un extrait de larve d'allomyrina dichotoma en tant que principe actif pour améliorer les rides de la peau ou pour hydrater la peau
WO2019225891A1 (fr) Composition contre le vieillissement de la peau contenant de l'irilin b
WO2019177327A1 (fr) Composition comprenant un extrait de schisandra chinensis en tant que principe actif pour la prévention, le soulagement ou le traitement de l'arthrite
KR101918773B1 (ko) 군소 추출물을 유효성분으로 포함하는 두피 개선 및 탈모 방지용 조성물
WO2011040770A2 (fr) Composition cosmétique de prévention de vieillissement et décolorante

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18761579

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18761579

Country of ref document: EP

Kind code of ref document: A1